MedTrace Logo

ZN-c3 + Gemcitabine in Pancreatic Cancer

NCT06015659 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.

The names of the study drugs involved in this study are:

* ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase)
* Gemcitabine (a nucleoside metabolic inhibitor)

Conditions

Interventions

DRUG

Zentalis

Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.

DRUG

Gemzar

Nucleoside metabolic inhibitor, per standard care via intravenous infusion.

Sponsors & Collaborators

  • Lustgarten Foundation

    collaborator OTHER

  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    collaborator INDUSTRY

  • Stand Up To Cancer

    collaborator OTHER

  • Brandon Huffman, MD

    lead OTHER

Principal Investigators

  • Brandon Huffman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-16
Primary Completion
2025-08-06
Completion
2027-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015659 on ClinicalTrials.gov